Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of autologous expanded bone marrow mesenchymal progenitor cells for non-hypertrophic nonunion
2010-022909-18Phase 2Active
- Sponsor
- Hospital General de l'Hospitalet
- Start
- Nov 2010
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of XCEL-M-ALPHA in fracture nonunion and pseudoarthrosis, sponsored by Hospital General de l'Hospitalet. Primary endpoints: Complete response at 12 months and Safety of XCEL-M-ALPHA application. Started Nov 2010; status: active.
02
Drugs
XCEL-M-ALPHA
03
Conditions
fracture nonunionpseudoarthrosis
Beyond the preview
Go deeper on 2010-022909-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022909-18.